What Is Surgical Menopause?

The HRT Index Editorial TeamIndependent women's health research

Published: May 15, 2026Last reviewed: August 2026

Editorial research — not medically reviewed by a clinician. Why this label

Last updated: August 4, 2026 · Last verified: August 4, 2026 · By The HRT Index Editorial Team. Educational research, not medical advice, and not reviewed by a clinician. See our medical review policy. Full disclosure.

Route your surgery history to the right next step

This page cannot diagnose surgical menopause or change a dose. When you are past urgent postoperative recovery and need help organizing symptoms, safety history, uterus status, and the right care setting, Find My HRT Path can help route the next conversation.

Build my HRT starting-point plan

What is surgical menopause? It is menopause caused by removal of both ovaries before natural menopause. The ovarian hormone change is immediate, although symptoms may not be. A hysterectomy alone does not cause surgical menopause if one or both ovaries remain. After early bilateral ovary removal, hormone therapy is generally recommended until the usual menopause age unless contraindicated.

Last verified: August 2026

What changes, what doesn’t, and what to do next.

Is this page for you?

Yes, if:

Both ovaries were removed, or are scheduled to be removed.
You had a hysterectomy and honestly are not sure what happened to your ovaries.
You are weighing ovary removal for cancer risk, endometriosis, an ovarian condition, or persistent pain.
Symptoms began after reproductive surgery and nobody explained why.
You need to know what belongs with your surgeon, oncology team, gynecologist, menopause clinician, or an online service.

No — start somewhere else, if:

You are in the first days or weeks after surgery with worsening pain, fever, heavy bleeding, repeated vomiting, wound problems, chest pain, or shortness of breath. Use your discharge instructions and contact the surgical team or emergency services as directed.
Your ovaries are intact and you think you are in natural perimenopause → start with the perimenopause symptoms checklist.
You are in active cancer treatment and need a hormone decision. That belongs with your oncology team first.
You need a personal medication dose changed today. This page gives you the evidence and the questions; it does not prescribe.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

Now the part that changes the answer. The usual hormone-therapy path can shift if your surgery treated a hormone-dependent cancer, if you have a personal history of breast cancer, if you have endometriosis, if your uterus remains, or if another medical condition changes what can be prescribed. Those are different conversations. We cover each one below.

And there is one more thing almost nobody explains before discharge: the estrogen dose used after early loss of both ovaries may not be the same as a low dose used only to calm hot flashes near the natural menopause age. The current international guideline for premature ovarian insufficiency gives a specific bone-protection dose benchmark, while also making clear that the best personal dose is not settled by one number.

The 7 facts that settle the question

#	Fact	What it means
1	Surgical menopause requires both ovaries to be removed before spontaneous menopause.	A bilateral oophorectomy or BSO causes surgical menopause.
2	A hysterectomy removes the uterus, not automatically the ovaries.	No periods after hysterectomy does not prove ovarian function stopped.
3	Removing one ovary is not surgical menopause.	The remaining ovary commonly continues producing hormones.
4	Removing both fallopian tubes is not surgical menopause.	Salpingectomy leaves the ovaries in place.
5	The ovarian change begins at surgery; symptom timing varies.	A quiet first week does not prove nothing changed, and a terrible first week is not automatically all hormonal.
6	Early loss of ovarian function changes the hormone-therapy conversation.	Current guidance generally supports treatment until the usual menopause age when no contraindication exists.
7	The procedure name cannot decide your safest treatment.	Uterus status, age, surgery reason, cancer history, endometriosis, and other health factors still matter.

One sentence to remember: no periods and no ovarian function are not the same fact.

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

Find My HRT Path takes about 90 seconds, needs no email, and is for education and routing only. It may show providers with which The HRT Index has affiliate relationships. FDA-approved and compounded options are labeled separately. How we make money.

What we actually verified for this page

Checked in August 2026:

The Menopause Society’s strict definition of surgical menopause.
Current hysterectomy, oophorectomy, and salpingectomy terminology.
The 2025 international evidence-based guideline for premature ovarian insufficiency, including hormone-therapy duration, bone-density dosing, endometriosis, BRCA, and testosterone recommendations.
The full Mayo Clinic trial protocol containing the “two-to-four-fold” dose statement and its “no consensus guideline” limitation.
The 2019 randomized Women’s Health Initiative estrogen-alone analysis by ovary status and age.
The February 2026 nationwide Danish mortality study.
The April 2026 BRCA1/2 cohort on hormone therapy after risk-reducing ovary removal.
The FDA’s February 2026 menopausal hormone-therapy labeling changes.
The FDA status of compounded menopause hormones and testosterone products.
Testosterone’s Schedule III controlled-substance status in the United States.
The live timing, no-email claim, educational-routing scope, and disclosure language of Find My HRT Path.

What we did not do: examine anyone, review anyone’s medical records, test a product, or complete a clinical consultation. This is editorial research produced under The HRT Index Verification Standard. It is not medical advice and has not been reviewed by a clinician.

What we deliberately left out: several precise-looking percentages and provider claims that could not be tied to a current primary source or did not belong on an early-awareness page. A number that cannot survive a source check does not become safer because it converts well.

What is surgical menopause — and which surgeries actually count?

Surgical menopause is induced menopause caused by removing both ovaries before spontaneous menopause. In a medical record it may appear as a bilateral oophorectomy or a bilateral salpingo-oophorectomy, usually shortened to BSO, which removes both ovaries and both fallopian tubes. Removing the uterus or fallopian tubes without removing both ovaries does not meet the strict definition. The Menopause Society uses this same bilateral-ovary-removal definition.

Let’s take the words apart, because the words are half the confusion.

Oophorectomy = removing an ovary.
Bilateral = both sides. Unilateral = one side.
Salpingo- = fallopian tube. A salpingo-oophorectomy removes a tube and ovary on the named side.
BSO = bilateral salpingo-oophorectomy: both tubes and both ovaries.
Adnexa = the ovary and fallopian tube beside the uterus. “Adnexa” alone is not enough; read the action and the side. “Bilateral adnexectomy” usually means both tubes and ovaries were removed.
Hysterectomy = removing the uterus. A total hysterectomy usually removes the uterus and cervix; it does not automatically remove the ovaries.

Before menopause, the ovaries are the main source of estradiol and progesterone and an important source of testosterone. The uterus is not the source of the ovarian hormones that define menopause. Remove the uterus and menstrual bleeding stops. Remove both functioning ovaries and ovarian production of estradiol and progesterone falls abruptly; adrenal and peripheral hormone production does not disappear.

That distinction is the whole ballgame.

The Procedure-to-Path Map

We built this because no single source we reviewed connects the procedure words, organs remaining, bleeding status, strict classification, practical meaning, and next question in one place.

Find the row that matches your paperwork.

Words that may appear in your record	What was removed or retained	What happens to periods?	Surgical menopause?	What it means in practice	Best next question
Hysterectomy; ovaries conserved	Uterus removed; one or both ovaries remain	Menstrual bleeding stops because the uterus is gone	No	Ovarian hormone production generally continues, although menopause may occur earlier on average after hysterectomy	“Does my operative report confirm that both ovaries were retained?”
Hysterectomy with unilateral oophorectomy	Uterus and one ovary removed; one ovary remains	Bleeding stops because the uterus is gone	No	The remaining ovary commonly continues ovarian function	“Which ovary remains, and does it need follow-up?”
Bilateral salpingectomy	Both fallopian tubes removed; ovaries remain	Periods continue unless the uterus was also removed	No	The tubes are not the ovaries. This procedure does not meet the definition of surgical menopause	“Were both ovaries definitely left intact?”
Bilateral oophorectomy; uterus retained	Both ovaries removed; uterus remains	Natural ovarian cycles and periods stop; some hormone regimens can cause scheduled bleeding	Yes, if performed before spontaneous menopause	Ovarian hormones fall abruptly. If systemic estrogen is used, the uterus normally requires progestogen protection	“What is the symptom and hormone plan, given that my uterus remains?”
Hysterectomy with BSO	Uterus, both tubes, and both ovaries removed	Periods stop	Yes, if performed before spontaneous menopause	Both ovaries and the uterus are absent. Estrogen-only therapy is often used when systemic hormone therapy is appropriate, but the surgery reason can change the plan	“Why were both ovaries removed, and what management plan applies to my diagnosis?”
Bilateral oophorectomy after spontaneous menopause	Both ovaries removed after menopause had already occurred	Periods had already stopped	Not a new onset under the strict definition	It is still bilateral ovary removal, but it does not start menopause for the first time	“At my age and for my diagnosis, what changes should I expect?”
Chemotherapy, pelvic radiation, or ovarian-suppression medication	Ovaries remain anatomically; function may be suppressed or damaged	Bleeding may stop or become irregular	No — this is treatment-induced or medically induced menopause	Ovarian function may or may not return depending on treatment, dose, age, and baseline function	“Is ovarian function expected to return, and how will my team assess it?”

How to read your operative report

Many women asking this question online do not know what was removed. That is not a personal failure. “Full hysterectomy” is not a precise medical inventory, and discharge paperwork is not always written in plain English.

Ask for:

The operative report — the surgeon’s account of what was done.
The pathology report — a record of tissue sent to the laboratory. It can corroborate which specimens were submitted, but it is not guaranteed to be a complete inventory of every structure retained.
The discharge summary.
The surgical consent form, if you are still trying to reconstruct what was planned.

Look for these words:

Look for	What it usually means
“Right ovary” and “left ovary”	Check separately whether each was removed, preserved, normal, or not visualized
“Bilateral oophorectomy,” “BSO,” or “bilateral salpingo-oophorectomy”	Both ovaries removed
“Ovaries conserved,” “ovaries preserved,” or “ovarian conservation”	Ovaries left in
“Unilateral oophorectomy”	One ovary removed
“Salpingectomy”	One or both fallopian tubes removed; read laterality
“Adnexectomy”	Removal of the ovary and tube on the named side; “bilateral” means both sides
“Specimens submitted”	Tissue sent to pathology; useful corroboration, not a complete retention list

If the paperwork is still unclear, ask the surgical office this in writing:

“Please confirm whether my uterus, cervix, right ovary, left ovary, right fallopian tube, and left fallopian tube were removed or retained.”

That sentence works better than asking whether the surgery was “complete” or “full.”

And here is the trap: partial hysterectomy and total hysterectomy describe how much of the uterus and cervix came out. They do not tell you whether your ovaries came out. A total hysterectomy can leave both ovaries intact.

The damaging admission

This map can classify the procedure. It cannot tell you whether hormone therapy is safe for you from the procedure name alone.

Your age, uterus status, reason for surgery, pathology, endometriosis history, cancer history, clotting history, liver health, migraines, cardiovascular risk, and current symptoms can all change the next decision.

That is why the right next move is not choosing a hormone from a chart. It is confirming what was removed and taking the right question to the clinician who knows why it was removed.

Does a hysterectomy cause surgical menopause?

No — not by itself. A hysterectomy removes the uterus, so menstrual bleeding stops. If one or both ovaries remain, ovarian hormone production generally continues and the operation does not meet the definition of surgical menopause. A prospective study did find nearly twice the risk of earlier ovarian failure after hysterectomy with ovarian preservation. That is an association, not proof that every hysterectomy causes ovarian failure.

Why periods stop but ovarian hormones can continue

A period is the shedding of the uterine lining. No uterus, no uterine lining to shed, no menstrual bleed.

The ovaries sit separately. If they remain and keep functioning, they can continue cycling and producing hormones. Ovulation can still occur after hysterectomy; there is simply no uterine bleeding to mark the cycle.

Which creates a strange problem: after a hysterectomy, you lose the signal most people use to recognize menopause. There is no “12 months without a period” to count.

But the clock can move

This is where most pages either overstate it — “hysterectomy causes menopause” — or wave it away — “your ovaries are fine.” Neither tells the whole truth.

A prospective study followed 406 women aged 30 to 47 who had hysterectomy without bilateral ovary removal and 465 controls with intact uteruses. Ovarian failure was defined in the study as an FSH level of at least 40 IU/L.

Overall ovarian-failure risk after hysterectomy: HR 1.92 (95% CI 1.29–2.86).
Estimated ovarian failure by four years: 14.8% after hysterectomy versus 8.0% in controls.
Hysterectomy plus removal of one ovary: HR 2.93 (1.57–5.49).
Hysterectomy with both ovaries retained: HR 1.74 (1.14–2.65).

The honest limit: this study shows an association. It cannot tell us whether the surgery itself accelerated ovarian failure, whether the underlying condition contributed, or whether both did.

Translation for real life: if you had a hysterectomy at 41 and kept both ovaries, you are not in surgical menopause. You may be more likely to reach menopause earlier than you otherwise would have, and you will not have a final period to date it. That is worth raising when symptoms change.

What hormones drop after both ovaries are removed?

Ovarian estradiol and progesterone production falls abruptly after both functioning ovaries are removed, and testosterone also declines. The background to a landmark New England Journal of Medicine trial summarized earlier endocrine studies as showing about an 80% fall in estradiol and 50% fall in testosterone after premenopausal bilateral oophorectomy. Those are group averages, not a home-testing target. The trial itself studied testosterone treatment after oophorectomy; it did not establish a universal post-surgery hormone level.

The ovaries provide about half of circulating testosterone production before menopause, with the adrenal glands and peripheral conversion contributing the rest. Even after natural menopause, ovaries can remain an androgen source. In a postmenopausal cohort, bilateral oophorectomy was associated with 25% lower testosterone than natural menopause: 15.5 versus 20.8 ng/dL. That study did not show that every symptom is caused by one hormone level.

If desire changed after surgery, you did not imagine it

If your libido fell off a cliff after ovary removal, that is not a moral failure, proof that your relationship is broken, or evidence that you are “not trying.” A major ovarian source of sex hormones disappeared in one operation.

But low desire is not diagnosed by a testosterone number alone. Pain, vaginal dryness, sleep loss, mood, medications, relationship context, body image, cancer treatment, surgical recovery, and other health conditions can all be part of the picture.

The right response is not “it is all in your head.” It is also not “testosterone fixes everyone.” The right response is a real sexual-health assessment.

Why we are not repeating the numbers you will see elsewhere

Commercial pages repeat claims such as a “95% drop in 24 hours,” a fixed percentage of symptom relief, or a guaranteed rate of restored sexual function.

We could not trace several of those claims to a primary study that supported the exact number and population. They are not on this page.

When you are frightened, precise-sounding numbers feel reassuring. But a number nobody can back up is worse than no number, because you may make a decision on it.

Why can surgical menopause feel harder than natural menopause?

Natural menopause usually arrives through a transition over years. Surgical menopause bypasses that transition when both ovaries are removed, so the hormonal change is abrupt. Symptoms can be faster and more intense, particularly when surgery happens well before the usual menopause age, but severity still varies from woman to woman.

Natural menopause gives you a ramp.

Surgery gives you a cliff.

That does not mean every woman falls the same distance. It means the physiology changed without the gradual lead-in of perimenopause.

	Natural menopause	Surgical menopause	Medically induced menopause
Cause	Ovarian function declines naturally	Both ovaries are removed before spontaneous menopause	Medication, chemotherapy, radiation, or ovarian suppression
Speed of ovarian change	Gradual	Abrupt at surgery	Variable
Perimenopause	Usually present	Bypassed	May be bypassed
Periods	Irregular, then stop	Natural periods stop; hysterectomy also stops bleeding	May stop or become irregular
Permanent?	Yes	Ovary removal is permanent	May be temporary or permanent
Biggest uncertainty	Timing of the final period	Exactly what was removed and why	Whether ovarian function may return
Where to start	Symptom and health review	Confirm the operation, then plan	Treating oncology or specialist team

A note on labels: surgical describes the cause. Premature describes ovarian insufficiency before 40. Early menopause generally means menopause from 40 through 44. Both ovaries removed at 35 can therefore be described as premature surgical menopause; removal at 43 is early surgical menopause.

Relief about surgery and grief about what changed can coexist. So can gratitude that cancer risk was reduced and anger that nobody explained the aftermath. None of those reactions cancel the others.

What are surgical menopause symptoms — and how fast do they start?

Surgical menopause symptoms can include hot flashes, night sweats, sleep disruption, mood or concentration changes, vaginal dryness, urinary symptoms, pain during sex, and changes in desire. The ovarian hormone change begins when both functioning ovaries are removed, but symptom timing varies. Anesthesia, medication, blood loss, stress, infection, and recovery can overlap. Current guidance treats vasomotor, genitourinary, sexual, psychological, bone, and cardiovascular health as distinct parts of the same follow-up plan.

How do you tell surgical menopause symptoms from recovery?

Feeling fine in week one does not prove nothing changed. Feeling terrible in week one does not prove it is all hormonal.

Symptom	Could be menopause-related?	What else may matter after surgery?	What to raise
Hot flashes or sweating	Yes	Fever, infection, medication reaction	Temperature, timing, accompanying symptoms
Insomnia	Yes	Pain, hospital disruption, anxiety, medication	Sleep pattern and pain control
Low mood or anxiety	Yes	Grief, anesthesia recovery, cancer diagnosis, prior mental-health condition	Severity, safety, support, treatment
Fatigue	Yes	Blood loss, anemia, infection, poor intake, medication, lost sleep	Postoperative review
Vaginal dryness	Yes	Healing restrictions, infection, pelvic-floor issues	Timing, examination, symptom-specific treatment
Brain fog	Yes	Anesthesia, sleep loss, stress, pain medication	Onset and whether it is improving
Palpitations	Possible	Medication, anemia, dehydration, thyroid or cardiac causes	Clinical assessment if new or concerning
Pelvic pain	Not specific to menopause	Normal healing or a complication	Follow the surgical team’s pain guidance
Heavy bleeding	Do not dismiss as menopause	Postoperative bleeding or another problem	Contact the surgical team urgently

Do not file these under “just menopause”

Use emergency services now for chest pain, severe breathing difficulty, fainting, signs of stroke, or another symptom your discharge instructions label an emergency.

Contact the surgical team promptly for worsening or severe pain, fever, repeated vomiting, bleeding heavier than your discharge instructions allow, new wound redness or drainage, wound opening, or other postoperative warning signs.

This is not a complete emergency list. Your own discharge instructions win.

And one more timing point: if you were already close to natural menopause, the change may feel different from surgery at 32. If both ovaries were removed after spontaneous menopause, the operation is still an oophorectomy, but it is not the first onset of menopause.

How long does surgical menopause last?

The anatomical change is permanent: removed ovaries do not regrow, so surgical menopause does not “end.” Symptoms are a different timeline. Hot flashes may change over years, while vaginal, urinary, sexual, bone, and cardiovascular concerns can need ongoing attention. There is no single countdown that covers all of it.

What the reader may mean by “How long?”	The useful answer
How long does surgical recovery last?	Recovery depends on the operation, approach, complications, and the surgeon’s instructions. It is not the same timeline as menopause symptoms.
How long does the ovarian hormone loss last?	Permanently. Both removed ovaries do not resume function.
How long do hot flashes and night sweats last?	There is no universal duration. They may improve, fluctuate, or persist, and treatment can change the course.
How long do vaginal and urinary symptoms last?	They often persist or progress without effective treatment rather than following one short clock.
How long is hormone therapy used after early ovary removal?	Current guidance generally supports treatment until the usual menopause age when no contraindication exists, then reassessment rather than an automatic stop.
How long do bone and cardiovascular follow-up matter?	Ongoing. They are long-term health domains, not symptoms with one finish date.

Anyone giving one number for all six questions is answering the wrong question.

Is hormone therapy usually recommended after surgical menopause?

For women who lose ovarian function well before the usual menopause age, current guidance generally recommends hormone therapy until that age when no contraindication exists, even if symptoms are mild. This is not the same clinical question as starting systemic hormone therapy for the first time decades after menopause. Uterus status, age, surgery reason, cancer history, and endometriosis still decide the regimen. The 2025 international POI guideline recommends treatment until the usual menopause age to reduce morbidity and mortality.

That sentence deserves to be much better known than it is.

The frightening headlines many women remember came from the Women’s Health Initiative. The FDA now emphasizes that the average participant was 63, more than a decade beyond the average menopause age. That population is not a clean stand-in for a 38-year-old who has just lost both ovaries. The FDA’s 2025–2026 labeling review explicitly revisited that mismatch.

The current 2025 international guideline says:

Hormone therapy is recommended for women with premature ovarian insufficiency until the usual menopause age, whether estrogen-deficiency symptoms are present or not.
When that age is reached, continuation becomes an individualized risk-benefit decision.
A woman with an intact uterus needs a progestogen with systemic estrogen to protect the endometrium.
BRCA1/2 carriers without a personal history of breast cancer should be told hormone therapy is an option after risk-reducing bilateral ovary removal.
A personal history of breast cancer changes the default.
Endometriosis can change the progestogen decision even after hysterectomy.

The default is not “everyone must take hormones.” The default is that early loss of ovarian function deserves an active plan, not silence.

Not sure whether the guideline default applies to you?
Age, uterus status, surgery reason, symptoms, risk history, state, and treatment preference all change the right starting point. Build my personalized HRT starting-point plan → Find My HRT Path takes about 90 seconds and flags when online care is not the right first step.

Does surgical menopause need a different estrogen dose?

Sometimes. A younger woman replacing hormones after early ovarian loss may need a different dose discussion from a woman using a low dose only for hot flashes near the natural menopause age. The 2025 POI guideline suggests at least 2 mg oral estradiol or 100 micrograms transdermal estradiol daily, or equivalent, to optimize bone density. That is a conditional, low-certainty recommendation — not a personal prescription. The guideline also calls for regular clinical review.

The Replacement Gap

This is the section we would fight hardest to keep.

A Mayo Clinic trial protocol studying women who had both ovaries removed before 46 states that current practice uses estrogen doses about two to four times higher than doses used for vasomotor symptoms after natural menopause. The same protocol says there were no consensus guidelines for the optimal dose. Its standard-dose comparison arm used a 100-microgram estradiol patch. Read the protocol, not a commercial paraphrase.

The protocol is useful. It is not a universal dosing rule.

Evidence source	What it actually says	What it does not say
2025 international POI guideline	At least 2 mg oral estradiol or 100 micrograms transdermal estradiol daily, or equivalent, is suggested to optimize bone density	That every woman must use that exact product or dose
Mayo trial protocol	Current practice was described as roughly 2–4 times the dose used for vasomotor symptoms after natural menopause; 100 micrograms transdermal was the standard arm	That a 2–4× multiplier is a settled guideline or a self-adjustment formula
FDA-approved product labeling	Gives product-specific indications, contraindications, strengths, and dosing instructions	A single universal “surgical menopause replacement dose”
Intact-uterus guidance	Progestogen protection is required with systemic estrogen; higher estrogen doses may require a higher progestogen dose	That estrogen dose can be considered without the uterus and progestogen plan

What we are not saying

We are not telling you a number to request or telling you that your current dose is wrong.

Route matters. Age matters. Your uterus matters. Why the ovaries were removed matters. Cancer history, endometriosis, migraines, clotting history, liver health, blood pressure, medication interactions, and response all matter.

What we are saying is this:

If both ovaries were removed young, you were started on a low dose, and you still feel terrible, “Is this being treated as symptom control or early ovarian-hormone replacement?” is a legitimate question.

Not a demand. A question.

Four questions worth writing down

“Given the age when both ovaries were removed, what goal are we treating: symptoms, bone protection, replacement until the usual menopause age, or all three?”
“How did you choose this dose and route for my history?”
“If my uterus remains, is the progestogen plan adequate for the estrogen dose?”
“When will we review symptoms, adherence, side effects, bone health, and whether the dose is doing the job?”

You have a legitimate dose question. Now route it to the right care setting.
Check which care path fits my history → The tool does not calculate or prescribe a dose. It helps identify whether routine online care, an in-person menopause clinician, the surgical team, or oncology should be the starting point.

What does the 2026 evidence say about hormone therapy after ovary removal?

Two large analyses help separate early treatment after ovary removal from late initiation many years after menopause. In the randomized Women’s Health Initiative estrogen-alone trial, women aged 50 to 59 with prior bilateral ovary removal had lower all-cause mortality with estrogen over 18 years. A 2026 Danish registry study found no increased overall mortality with menopausal hormone therapy and a lower mortality hazard in a bilateral-oophorectomy subgroup. Neither result means treatment guarantees longer life.

Study	Design and population	What it found	What it cannot prove
Women’s Health Initiative estrogen-alone analysis, 2019	Randomized trial of 9,939 women with prior hysterectomy; oral conjugated equine estrogens 0.625 mg/day versus placebo; ovary status examined	Among women aged 50–59 with prior BSO, cumulative all-cause mortality over 18 years was HR 0.68 (95% CI 0.48–0.96) with estrogen	The result does not establish the best product, route, or dose for every younger woman with surgical menopause
Same WHI analysis	Women aged 70–79 with prior BSO	During treatment, the global index was less favorable: HR 1.42 (1.09–1.86)	Findings in older initiators should not be transplanted onto women treated soon after early ovary removal — or vice versa
Danish nationwide registry, 2026	876,805 women; median 14.3 years of follow-up	Menopausal hormone therapy was not associated with increased all-cause mortality overall: adjusted HR 0.96 (0.93–0.98)	An observational registry cannot prove that hormone therapy caused the difference
Danish bilateral-oophorectomy subgroup	Women who underwent bilateral oophorectomy at 45–54	Hormone-therapy use was associated with a 27% to 34% lower mortality hazard, depending on duration	The subgroup was small, treatment was not randomized, and healthy-user bias may remain

The Danish bilateral-oophorectomy subgroup included 703 women aged 45 to 54. Among women in that subgroup who died, median age at death was 60.9 for hormone-therapy users and 56.6 for nonusers.

That is not a four-year life-expectancy guarantee. It is a descriptive result among the decedents in an observational subgroup, not a personal survival forecast.

Now the honest limits

We would be doing exactly what we criticize elsewhere if we stopped at the favorable numbers.

The Danish subgroup was observational. Women who use hormone therapy may differ from nonusers in health, access, education, follow-up, and other ways the analysis cannot fully remove.
The Danish study excluded women with several major conditions, including prior thromboembolism, liver disease, and breast, uterine, or ovarian cancer. It does not answer those histories.
The WHI used oral conjugated equine estrogens, not every product and route now available.
The WHI age pattern matters. Treatment near early ovarian loss and first initiation at 72 are genuinely different questions.
Mortality is not the only outcome. Symptoms, bone density, bleeding, sexual health, side effects, personal values, and the reason for surgery still matter.

What this evidence supports: early surgical menopause deserves an active treatment discussion, and evidence from older initiators should not be used to shut that discussion down.

What it does not support: “HRT is good for everyone,” “HRT is bad for everyone,” or “this regimen will make you live longer.”

Read the 2019 WHI analysis. Read the 2026 Danish study.

Do you need progesterone if your uterus is gone?

Usually not for endometrial protection after a complete hysterectomy, because there is no endometrium to protect. If the uterus or functioning endometrium remains, systemic estrogen normally requires a progestogen. Endometriosis and some cancer histories can change the usual post-hysterectomy rule.

If the uterus remains

Current guidance is direct: a progestogen should be combined with systemic estrogen in women with an intact uterus to reduce the risk of endometrial hyperplasia and cancer.

If higher estrogen doses are used, the 2025 POI guideline says the progestogen dose may also need to be increased. That is another reason the dose conversation cannot be separated from uterus status.

Unscheduled bleeding needs assessment. Do not assume bleeding on hormone therapy is automatically harmless.

If the uterus was completely removed

Estrogen-only therapy is commonly used when systemic treatment is appropriate because endometrial protection is no longer the job.

But “no uterus” is not the end of the history.

A subtotal or supracervical hysterectomy may leave cervical and sometimes residual endometrial tissue; the operative details matter.
Endometriosis can persist outside the uterus.
Cancer treatment can change what is appropriate.
The treatment goal may involve symptoms that need something other than systemic estrogen.

The endometriosis exception is not a footnote

The current international POI guideline recommends combined estrogen-progestogen hormone therapy even after hysterectomy for women with a history of endometriosis, to reduce concern about recurrence or malignant transformation of residual disease.

If endometriosis was the reason for surgery, say it out loud at every hormone consultation. This is not a minor exception to the usual post-hysterectomy rule.

What changed in FDA hormone labeling in 2026?

On February 12, 2026, the FDA announced approved labeling changes to an initial group of six menopausal hormone-therapy products. Certain cardiovascular disease, breast cancer, and probable dementia statements were removed from the boxed warning on those products.

Two things people get wrong:

The action did not instantly rewrite every label for every hormone product. The FDA said 29 companies had submitted proposed changes, and the first approved batch contained six products.
The FDA did not seek removal of the endometrial-cancer boxed warning for systemic estrogen-alone products used by women with a uterus.

“FDA removed the black-box warning from HRT” is too broad to guide a real prescription. Check the current label for the exact product.

Read the FDA’s February 2026 announcement.

FDA-approved and compounded hormones are not the same category

FDA-approved hormone therapy	Compounded hormone product
Reviewed by the FDA for the approved formulation, indication, manufacturing, labeling, safety, and effectiveness standards	Not FDA-approved as a finished drug
Has official prescribing information	Formulation and labeling depend on the prescription and compounder
Can use hormones chemically identical to hormones made by the body, depending on the product	“Bioidentical” does not establish FDA approval, greater safety, or greater effectiveness
Can be checked in Drugs@FDA and, where applicable, the Orange Book	Does not appear there as an approved finished product
Generally preferred when an approved product meets the clinical need	May be considered for a specific clinical need that an approved product cannot meet, but its status does not become equivalent

The FDA says it does not have evidence that compounded products marketed as “bioidentical” are safe and effective, or safer or more effective than FDA-approved menopausal hormone therapy. The 2025 POI guideline also recommends against compounded “bioidentical” estrogen and progesterone because efficacy and safety data are lacking.

Read the FDA’s compounded-hormone explanation.

What is supported about testosterone after ovary removal?

Both ovaries are an important androgen source, and testosterone can fall substantially after bilateral oophorectomy. The evidence-based indication for systemic testosterone therapy in women is hypoactive sexual desire disorder — persistent low desire that causes personal distress after a biopsychosocial assessment. Testosterone is not an evidence-based cure-all for fatigue, brain fog, weight, mood, or disease prevention. That is the conclusion of the international consensus statement.

Here is the full picture:

A testosterone blood level does not diagnose HSDD.
Other causes of low desire should be considered: pain, vaginal symptoms, medication effects, sleep, mood, relationship context, surgery recovery, and cancer treatment.
Evidence supports physiologic-dose transdermal treatment for appropriately assessed postmenopausal women with HSDD.
Long-term safety data remain limited.
The consensus statement recommends against compounded testosterone and against preparations — including pellets and injections — that produce supraphysiologic levels.
The 2025 POI guideline says testosterone should be considered for HSDD after iatrogenic ovarian insufficiency when other biopsychosocial causes have been excluded.

The U.S. approval gap

There is no FDA-approved testosterone product for women in the United States. FDA-approved testosterone products are approved for men with specified medical causes of low testosterone. Prescribing one of those products to a woman is off-label; off-label does not mean FDA-approved for women.

A common claim says no national regulator anywhere has approved a women-specific testosterone product. That is false. Australia’s Therapeutic Goods Administration has approved ANDROFEME 1 for HSDD in postmenopausal women.

That distinction matters:

United States: no FDA-approved testosterone product for women.
Australia: a women-specific product is approved for a defined indication.
Compounded U.S. product: not FDA-approved, even when legally prescribed.

Testosterone is controlled in the United States

Testosterone is a Schedule III controlled substance in the United States. It requires a prescription from an authorized clinician and must be handled under federal and applicable state controlled-substance rules.

There is no legitimate over-the-counter route around that. “No prescription needed” is not a convenience; it is a warning sign.

Check the DEA schedule. Check the FDA’s current testosterone status. Check Australia’s ANDROFEME registration.

Low desire and vaginal pain are not the same problem

If your main problem is vaginal dryness, burning, urinary symptoms, or pain during sex, testosterone may not be the direct first tool. Local vaginal treatment and pelvic-floor assessment may fit the symptom better.

→ Read our guide to vaginal estrogen

What if your surgery was for cancer, BRCA, or high genetic risk?

BRCA-related risk-reducing surgery without a personal cancer history is not the same hormone decision as surgery during or after hormone-sensitive cancer. Current guidance says BRCA1/2 carriers without a personal history of breast cancer should be told hormone therapy is an option after risk-reducing bilateral salpingo-oophorectomy. A personal cancer history requires treatment-specific oncology input.

BRCA1 or BRCA2, with no personal history of breast cancer

The current 2025 international guideline supports discussing hormone therapy after risk-reducing ovary removal.

A 2026 multicenter cohort included 919 cancer-free women with BRCA1 or BRCA2 pathogenic variants who had risk-reducing bilateral ovary removal and no prior mastectomy. During an average 8.8 years of follow-up:

Ever-use of estrogen-only therapy was not associated with increased breast-cancer risk: adjusted HR 0.89 (95% CI 0.48–1.63).
Combined estrogen-progestin therapy was not associated with a statistically significant change in risk: adjusted HR 1.06 (0.67–1.68).
Each year of estrogen-only use was associated with lower risk among the BRCA1 subgroup, but this was an observational association, not proof of a protective drug effect.

Read the April 2026 JAMA Network Open study.

The damaging admission in the BRCA evidence

The 2026 study is reassuring. It is not universal proof.

It was retrospective, not randomized.
It came from three centers in Israel.
The cohort contained a limited range of pathogenic variants and was largely shaped by founder variants.
Women with prior cancer or prior risk-reducing mastectomy were excluded.
The average age at ovary removal was 47.6, older than many BRCA1 risk-reducing procedures.
Selection bias can survive statistical adjustment.

The study authors themselves say the findings may not generalize to every woman with a BRCA variant.

The evidence supports a real hormone-therapy conversation. It does not replace genetic counseling, breast-risk planning, or specialist care.

Personal history of breast, ovarian, endometrial, or another hormone-dependent cancer

Different conversation. Full stop.

Cancer type, stage, receptor status, pathology, current treatment, recurrence risk, and the specific symptom being treated can all change the answer.

The current POI guideline:

Generally does not recommend systemic hormone therapy after breast cancer.
Allows individualized consideration in some women after early-stage low-risk endometrial adenocarcinoma.
Allows consideration after some epithelial ovarian cancers.
Advises avoiding hormone therapy in specified hormone-dependent ovarian or uterine tumors.
Calls for individualized risk-benefit decisions after gynecologic or breast cancer.

No online menopause service should override an active oncology plan. If a service acts as though a checkbox can settle that history, leave.

When systemic hormones are not appropriate or are not your choice, real options still exist: FDA-approved nonhormonal treatments for vasomotor symptoms, symptom-specific vaginal and urinary care, sleep and mood treatment, pelvic-floor therapy, and bone and cardiovascular risk management.

→ See nonhormonal menopause options

What if surgery was for endometriosis?

Removing the uterus and ovaries does not guarantee that all endometriosis tissue or pain disappears. Residual disease can persist, which is why current guidance recommends combined estrogen-progestogen therapy after surgical ovarian loss in women with endometriosis even after hysterectomy.

If disease was complex, bowel or bladder involvement was present, pain continues, or the diagnosis is uncertain, start with an experienced in-person clinician.

Is your situation too complicated for a general answer?
Cancer-related surgery belongs with the oncology team first. Complex endometriosis and unexplained postoperative pain usually belong in person. See whether online care fits my situation → Find My HRT Path will tell you when online care is a reasonable starting point — and when it is not.

What are the long-term health considerations after early surgical menopause?

Early loss of ovarian function is associated at the population level with concerns involving bone, cardiovascular health, cognition, mood, sleep, sexual health, and overall mortality. These findings are not a personal forecast. Age at surgery, reason for surgery, baseline health, treatment, and other risk factors change the picture.

The current 2025 guideline treats early ovarian insufficiency as more than a symptom problem:

Hormone therapy is recommended until the usual menopause age to reduce morbidity and mortality when no contraindication exists.
Bone-density measurement with DXA is recommended at diagnosis of premature ovarian insufficiency where available.
Cardiovascular risk should be assessed.
Blood pressure, weight, smoking status, lipids, and diabetes risk should be reviewed.
The potential cognitive and neurologic consequences should be discussed when bilateral oophorectomy is planned before 45, particularly for women at average ovarian-cancer risk.
Sexual wellbeing and psychological health deserve direct assessment, not silence.

What older observational data found

The Nurses’ Health Study followed 29,380 women who had hysterectomy for benign disease: 16,345 with bilateral oophorectomy and 13,035 with ovarian conservation.

Outcome	Bilateral oophorectomy versus ovarian conservation
All-cause mortality	HR 1.12 (95% CI 1.03–1.21)
Fatal plus nonfatal coronary heart disease	HR 1.17 (1.02–1.35)
Breast cancer	HR 0.75 (0.68–0.84)
Ovarian cancer	HR 0.04 (0.01–0.09); number needed to treat reported as 220
Lung-cancer incidence	HR 1.26 (1.02–1.56); number needed to harm reported as 190
Never-users of estrogen who had surgery before 50	Higher all-cause mortality, coronary heart disease, and stroke in the study
Approximate 35-year projection in that cohort	One additional death per nine oophorectomies

Read the study.

Please read this part carefully

Those are population associations, not your personal clock.

The study was observational, included women having hysterectomy for benign disease, and reflects surgical and treatment patterns from earlier decades. It cannot tell one woman what will happen or what decision she should make.

Nobody should read that table and conclude, “My life has been shortened.”

What it says is that early ovary removal has downstream consequences worth managing. That is a different message — and a useful one.

Three areas worth putting on the follow-up plan:

Bone: ask whether and when a DXA scan is appropriate, especially after very early ovary removal or other bone-risk factors.
Heart and metabolism: blood pressure, lipids, glucose risk, smoking, activity, weight, and family history belong in routine care.
Brain, sleep, mood, and sexual health: symptoms deserve assessment, but hormone therapy is not an FDA-approved treatment to prevent dementia and should not be sold as one.

Why do so few women leave surgery with a menopause plan?

The care gap is documented, not invented. In a peer-reviewed audit of 36 premenopausal women who underwent BSO for benign disease at one UK hospital, 41.7% had no documented hormone-therapy discussion, only 5.6% had the discussion before surgery, and therapy was prescribed to 24% despite only one documented contraindication.

Read the 2017 audit.

That is a small, single-hospital UK study. It is not a U.S. national rate.

But the failure it exposes is recognizable: the operation has an owner; the long-term menopause plan often does not.

Surgeons operate. Oncologists focus on cancer. Primary care may not have the operative record. A gynecologist may assume somebody else handled hormones. The woman recovering from surgery becomes the person expected to connect the system.

Which means this, plainly: nobody may chase you about this.

That is unfair while you are recovering. But it is better to know it than to wait for a call that never comes.

You now have the words to raise it:

“Both ovaries were removed before natural menopause. Who owns my surgical-menopause follow-up, and what is the plan for symptoms, bone health, cardiovascular risk, sexual health, and hormone or nonhormonal treatment?”

Can online menopause care handle surgical menopause?

Sometimes. Online care can be a reasonable route for a stable, clearly documented case that does not need an examination or oncology coordination. Recent surgery, unclear anatomy, active cancer treatment, severe symptoms, complex endometriosis, or a need for physical examination belongs with the treating or in-person team first.

Situation	Better starting point	Why
Surgery was recent and recovery symptoms are changing	Surgical team	Menopause, medication effects, and postoperative complications can overlap
Surgery treated cancer or is part of active cancer care	Oncology and gynecology teams	Tumor type, receptor status, treatment, and recurrence risk matter
Operative details are unclear	Surgical office or gynecologist	The anatomy must be confirmed before routine hormone decisions
Persistent pelvic pain or complex endometriosis	Experienced in-person clinician	Examination, imaging, and disease-specific management may be needed
Stable benign-history case with clear records and routine ongoing management	Online or in-person menopause care may fit	The remaining question may be medication fit, route, follow-up, and access
Main problem is vaginal or urinary symptoms	Clinician who can assess local treatment and other causes	Systemic treatment is not the only path
HSDD and testosterone are being considered	Clinician prepared to perform a biopsychosocial assessment and controlled-substance follow-up	A blood level alone does not diagnose HSDD, and U.S. testosterone is Schedule III

What online care can do well: improve access, review a clear history, discuss FDA-approved routes, manage routine prescriptions where appropriate, and provide follow-up without a long local wait.

What it cannot replace: postoperative triage, a physical examination, cancer-team coordination, complex pelvic-pain workup, or a clinician who has not received the records that change the decision.

Routine follow-up should not be reduced to lab access. The current POI guideline calls for regular clinical review addressing individualized risk factors and adherence. Labs can matter for other diagnoses, safety questions, or testosterone monitoring, but “orders labs” is not by itself proof that a service can manage surgical menopause well.

Know what happened, but not who should manage it?
Match my situation to the right care path → The result is educational routing. A licensed clinician still makes treatment decisions.

What should you verify before choosing care?

Five questions reveal whether a clinic or clinician can actually handle your case. Ask before entering payment details or assuming that a general “menopause care” label includes surgical menopause.

Will you manage my exact surgical history? State the date, age at surgery, reason, whether the uterus remains, whether both ovaries were removed, and whether cancer or endometriosis was involved.
Who makes the treatment decision and who handles escalation? Ask what happens if symptoms, bleeding, pain, or a risk-history issue requires examination or specialist care.
Is each prescribed product FDA-approved or compounded? Ask by product name, strength, route, and manufacturer or compounding pharmacy. An NDC number alone does not turn a compounded product into an FDA-approved finished drug.
What monitoring is actually included? Ask about follow-up timing, refill review, blood-pressure or bone-health coordination, testosterone monitoring when relevant, and who receives outside records.
What is the total cost and how do you leave? Separate visit, membership, medication, laboratory, pharmacy, renewal, and cancellation costs. Confirm the amount during intake or checkout instead of relying on an unlabeled estimate.

On insurance: a carrier logo does not prove that your specific plan, clinician, visit type, medication, or pharmacy claim is covered. Verify the plan by name.

On treatment format: “bioidentical,” “natural,” and “customized” are marketing words unless the page also states whether the finished product is FDA-approved or compounded.

What should you ask before both ovaries are removed?

Before consent, two questions deserve clear answers: does each ovary need to come out, and what is the menopause plan if both do? Where removal is necessary for cancer treatment or major inherited risk, the benefit can be substantial. Where surgery is for benign disease in a younger average-risk woman, ovarian conservation deserves an explicit discussion rather than an automatic “take everything.”

The 12 questions

About the operation:

Is my uterus being removed?
Is my cervix being removed?
Are both fallopian tubes being removed?
Is one ovary being removed, or both?
Under what circumstances could the plan change during surgery?
How and when will I be told if both ovaries come out unexpectedly?

About why:

Why does each ovary need to be removed in my case?
Is conserving one or both ovaries medically reasonable for me?

About what happens afterward:

Who will manage surgical-menopause symptoms and long-term follow-up?
If hormone therapy is appropriate, when will it start and what could delay it?
Does keeping or removing the uterus change the plan?
When is the first review, and what happens if the first plan does not control symptoms?

Fertility questions belong before surgery

Removing both ovaries ends natural egg production. Options depend on what has already been preserved and whether the uterus remains.

Ask:

Is egg or embryo preservation medically and practically possible before surgery?
Is there time for fertility referral without compromising treatment?
If the uterus remains, could a pregnancy using a previously frozen or donor egg or embryo be possible after specialist assessment?
If hysterectomy is also planned, what family-building options should be discussed now?

The current POI guideline recognizes oocyte donation as an established pregnancy option after ovarian insufficiency. It does not make every woman medically eligible to carry a pregnancy; that requires individual assessment.

What should you do if surgery already happened?

Start by confirming whether zero, one, or two ovaries remain. Then identify who owns follow-up. Trying to choose treatment without knowing what was removed is a nearly impossible position to think clearly from.

Step 1 — Get the records

Request the operative report, pathology report, discharge summary, medication list, and follow-up instructions.

Step 2 — Confirm the anatomy in writing

Use the exact sentence from earlier:

“Please confirm whether my uterus, cervix, right ovary, left ovary, right fallopian tube, and left fallopian tube were removed or retained.”

Step 3 — Write a symptom timeline

Record:

Symptom
Date it began
Frequency
Severity
What it stops you doing
Whether it is improving or worsening
Medications started or stopped around the same time

Two weeks of organized notes can be more useful in an appointment than two hours of anxious searching.

Step 4 — Find the owner

Surgeon? Gynecologist? Gynecologic oncologist? Medical oncologist? Primary care? Menopause clinician?

Somebody has to own the next plan. If the answer is “nobody,” that is the first problem to solve.

Step 5 — Separate routine from urgent

Recent surgery plus a new severe or worsening symptom means following the surgical team’s instructions, not waiting for a routine telehealth appointment.

Copy-and-paste Surgical Menopause Appointment Card

Procedure and date: Reason for surgery: Uterus: removed / retained / unsure Right ovary: removed / retained / unsure Left ovary: removed / retained / unsure Fallopian tubes: removed / retained / unsure Natural menopause before surgery: yes / no / unsure Current medication and route: Three symptoms affecting me most: 1. 2. 3.

Questions I need answered:

Does my procedure meet the definition of surgical menopause?
Who owns my ongoing follow-up?
What is the goal of treatment at my age?
Does my uterus, cancer history, or endometriosis change the regimen?
What is the plan for bone, cardiovascular, sexual, vaginal, urinary, sleep, and mood health?
When will we review whether the plan is working?

What questions are women actually asking?

We reviewed public forum discussions for language and decision friction — not for medical evidence.

These quotations show the uncertainty surrounding surgery. They are not medical evidence, testimonials, or proof of typical outcomes.

If your question is in that list, you are asking the right question. The problem is not that you failed to understand one word. The problem is that the anatomy, hormone change, recovery, long-term plan, and care route were rarely assembled in one place.

That is what this page is for.

How did The HRT Index research this page?

This page was produced under The HRT Index Verification Standard. We checked medical definitions, current guidelines, regulatory status, peer-reviewed studies, and the live scope of the site’s routing tool. We removed commercial facts that did not belong to the intent and did not publish claims we could not tie to a current source.

Who created it: The HRT Index Editorial Team. No clinician reviewer has been invented or implied.

How it was evaluated: The HRT Index evaluates online-care options on five pillars, in this exact order: clinical legitimacy, care quality, medication fit, price transparency, access. We do not publish a numeric provider score on this page.

Why this page exists: because “my periods stopped” and “my ovarian function stopped” are constantly treated as the same fact. They are not. Getting that wrong can send a woman down the wrong path for years.

Commercial relationship: this article does not recommend or link directly to a paid provider. Find My HRT Path may display providers with which The HRT Index has affiliate relationships. If a reader starts care through an eligible link, The HRT Index may earn a commission at no extra cost to the reader. → Full affiliate disclosure

Think we got something wrong? → Tell us. We publish corrections.

Frequently asked questions about surgical menopause

Is surgical menopause immediate?

The loss of ovarian function begins when both functioning ovaries are removed. Symptoms may become noticeable quickly or later, and normal surgical recovery can make the first weeks hard to read.

Is surgical menopause permanent?

Yes. Removal of both ovaries is permanent. Symptoms and treatment needs can change over time, but the ovaries do not regrow or resume function.

Does every hysterectomy cause surgical menopause?

No. Hysterectomy removes the uterus. It causes surgical menopause only when both ovaries are also removed before spontaneous menopause.

Can you have surgical menopause if one ovary remains?

Not under the strict definition, which requires both ovaries to be removed. The remaining ovary commonly continues producing hormones, although unilateral ovary removal is associated with an earlier average age at natural menopause in observational research.

Does removing both fallopian tubes cause menopause?

No. Bilateral salpingectomy removes the tubes, not the ovaries. With the ovaries retained, it does not meet the definition of surgical menopause.

Can surgical-menopause symptoms start weeks later?

Yes. Symptoms do not follow one clock. A quiet first week does not mean the hormonal change did not happen. New or worsening postoperative symptoms still need to be interpreted in the surgical context.

How do you know you are in menopause after hysterectomy?

First confirm whether the ovaries remain. If both were removed before spontaneous menopause, the procedure establishes surgical menopause. If one or both remain, periods cannot be used to date menopause, so symptoms, age, history, and clinical assessment matter.

Is surgical menopause worse than natural menopause?

It can be more abrupt and intense because the gradual transition is bypassed. “Worse” is not universal. Some women have severe symptoms, some have mild symptoms, and some notice little at first.

How long do surgical-menopause symptoms last?

There is no single number. Surgical recovery, hot flashes, sleep disruption, vaginal and urinary symptoms, treatment duration, and bone or cardiovascular follow-up all run on different timelines.

Do you always need hormone therapy after surgical menopause?

No treatment is right for every woman. Current guidance generally recommends hormone therapy after early loss of ovarian function until the usual menopause age when no contraindication exists, but cancer history, endometriosis, uterus status, and other medical factors can change the plan.

Do you need progesterone after hysterectomy?

Usually not for endometrial protection after a complete hysterectomy. Endometriosis, a subtotal hysterectomy, residual tissue, cancer history, or another clinical goal can change that answer.

Can you use vaginal estrogen after surgical menopause?

Local vaginal estrogen is commonly used for vaginal and urinary symptoms. A cancer history or current cancer treatment should be discussed with the relevant oncology and gynecology teams.

Is surgical menopause the same as premature menopause?

No. Surgical describes the cause. Premature describes ovarian insufficiency before 40. Both ovaries removed at 35 would be premature surgical menopause.

Do blood tests diagnose surgical menopause?

Documented removal of both ovaries before spontaneous menopause establishes surgical menopause; an extra blood test is not needed to prove what the surgery did. If the ovaries remain after hysterectomy and menopause timing is uncertain, a clinician may use symptoms, history, examination, and selected testing.

Can you get pregnant after both ovaries are removed?

You cannot conceive naturally with your own newly released eggs after both ovaries are removed. If eggs or embryos were preserved, or donor eggs or embryos are used, carrying a pregnancy may still be possible when the uterus remains and a specialist finds it medically appropriate. After hysterectomy, you cannot carry a pregnancy.

Is chemotherapy-induced menopause the same thing?

No. Chemotherapy, pelvic radiation, and ovarian-suppression medication can reduce or stop ovarian function without removing the ovaries. That is treatment-induced menopause, and function may or may not return.

Does surgical menopause affect libido?

It can. Ovarian hormone loss, vaginal pain, sleep, mood, medications, cancer treatment, relationship context, and recovery can all contribute. Persistent low desire causing distress deserves a full assessment, not a testosterone level by itself.

Does insurance cover hormone therapy after surgical menopause?

Coverage depends on the plan, clinician, product, pharmacy, prior-authorization rules, and whether visits and medications are billed separately. Verify each part with the insurer and provider by name.

What should you do next?

Three steps, in order:

Confirm — do both ovaries remain, one, or neither? Get the operative report.
Route — who owns follow-up: surgeon, oncology, gynecology, primary care, an in-person menopause clinician, or appropriate online care?
Prepare — bring the procedure details, pathology, symptom timeline, medication list, and questions from this page.

You do not have to become an expert in your own endocrinology.

You need to know what was removed, what changed, and which question belongs in the next room.

Still not sure which HRT program is right for you? Take our free 90-second matching quiz.

Find My HRT Path →

It matches your situation to a reasonable starting point and flags when online care is not the right first step. It does not diagnose surgical menopause, prescribe medication, or replace a licensed clinician.

Educational content only. This page is not medical advice and is not a substitute for care from a qualified clinician who knows your history. If you are in the first weeks after surgery with worsening symptoms, use your discharge instructions and contact the surgical team or emergency services as directed.

Sources

Need help choosing the right care route?

The free Find My HRT Path tool can help organize your surgery history, symptoms, safety flags, state, and treatment preferences. It also flags when online-only care is not the right starting point.

Keep reading: